Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCGR program
- Development stage
- Preclinical
- Lead developer
- Structure Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The GCGR program is an oral small-molecule drug candidate being developed by Structure Therapeutics (formerly ShouTi) for the treatment of obesity. It acts as an agonist of the glucagon receptor (GCGR), a G protein-coupled receptor that plays a critical role in glucose homeostasis and energy balance. By activating GCGR, the drug aims to increase energy expenditure, enhance lipid oxidation, and promote weight loss. This program is part of Structure Therapeutics' broader portfolio of oral small-molecule incretin mimetics and is currently in the preclinical stage of development.
- Other names
- ShouTi GCGR program
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on GCGR program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCGR program.